Transformational therapies for

age-related degenerative diseases

about us

Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for patients with age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs, focusing on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways and neuroinflammation. Sironax is currently conducting early clinical studies with SIR0365 and SIR2446, in addition to ongoing preclinical research.

more

  • 2017-09
    Sironax (Cayman) founded
  • 2018-06
    Seed financing
  • 2019-04
    First RIPK1i preclinical candidate SIR0365 nominated
  • 2019-09
    Series A financing
  • 2019-11
    First healthy subject dosed for SIR0365
  • 2020-08
    Healthy subject Ph1a completed for SIR0365
  • 2020-12
    First Ph1b patient study initiated SIR0365
  • 2021-08
    Second Ph1b study initiated for SIR0365
  • 2021-09
    Biologics programs jump-started
  • 2021-12
    • First healthy subject dosed for SIR2446
    • SIR0365 first Ph1b patient study topline data readout
  • 2022-08
    Series B financing
  • 2022-08
    Series B financing
  • 2021-12
    • First healthy subject dosed for SIR2446
    • SIR0365 first Ph1b patient study topline data readout
  • 2021-09
    Biologics programs jump-started
  • 2021-08
    Second Ph1b study initiated for SIR0365
  • 2020-12
    First Ph1b patient study initiated SIR0365
  • 2020-08
    Healthy subject Ph1a completed for SIR0365
  • 2019-11
    First healthy subject dosed for SIR0365
  • 2019-09
    Series A financing
  • 2019-04
    First RIPK1i preclinical candidate SIR0365 nominated
  • 2018-06
    Seed financing
  • 2017-09
    Sironax (Cayman) founded
Pipeline
more
RESEARCH AREAS
more
CAREERS
more